Aug 15, 2022
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
Aug 15, 2022
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 28, 2022
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
Jul 20, 2022
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
Jul 18, 2022
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Jul 14, 2022
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
Jun 21, 2022
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
Jun 13, 2022
AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention
May 19, 2022
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
 4   5   6   7   8     9    10   11   12   13   14 
 <<   <   >   >>